Status:
RECRUITING
Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome
Lead Sponsor:
Al-Mustansiriyah University
Conditions:
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in wo...
Detailed Description
The goal of this clinical trial is to learn if adding Quercetin or Alpha-Lipoic Acid (ALA) to metformin can better treat PCOS symptoms and improve safety, metabolic health, and quality of life in wome...
Eligibility Criteria
Inclusion
- • Newly diagnosed patients should be at reproductive aged from 18-40 years.
- Patients diagnosed with presence of micro polycystic ovaries at ultrasound.
- Oligomenorrhea with inter-menstrual intervals longer than 35 days.
- Clinical or biochemical signs of hyperandrogenism (acne, hirsutism).
- Normal PRL levels.
Exclusion
- • Presence of enzymatic adrenal deficiency and/or other endocrine disease, including diabetes.
- Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction).
- Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs.
- Pregnant women.
Key Trial Info
Start Date :
September 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07182526
Start Date
September 20 2025
End Date
May 1 2026
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mustansiriyah University/ College of Pharmacy
Baghdad, Karkh, Iraq, 00964